SARcode $44mn for PhIII dry eye study
This article was originally published in Scrip
Executive Summary
SARcode Bioscience, a Brisbane, California-based ophthalmic biopharmaceutical company, has landed a very significant $44 million B series from venture backers, giving the company the funds its needs to take its lead candidate, SAR 1118, into a Phase III trial for dry eye syndrome.